NASA Artemis II Data Methodology Challenge
The Living Abstract
A typographic data explorer for small-cohort analysis. Findings self-organize by statistical prominence. Zoom to reveal depth: → →
Cross-Modal Findings4
Astronaut 2 exhibited a significant immune shift concurrent with sleep disruption during transit phase, suggesting a stress-mediated inflammatory cascadeTransit
Change-point: day 4 · conf 94% · IL-6
IL-6 ↔ Sleep Efficiency r = -0.82
IL-6
1.2 – 5.9— no sample day 6 —
Sleep Efficiency
0.6 – 0.9Astronaut 3 demonstrated a coordinated neuroendocrine response linking cortisol, melatonin phase shift, and NK cell activity decline during transitTransit
Change-point: day 5 · conf 91% · NK_cell_pct, cortisol
Cortisol ↔ NK Cell Pct r = -0.71
Melatonin Onset ↔ NK Cell Pct r = -0.64
Cortisol
11.8 – 20.4NK Cell Pct
9.8 – 18.2— no sample day 3 —
Melatonin Onset
21.3 – 23.4Astronaut 1 showed cortisol elevation with concurrent heart rate variability depression during transit, recovering partially post-flightTransit
Change-point: day 3 · conf 88% · cortisol, HRV_RMSSD
Cortisol ↔ HRV RMSSD r = -0.76
Cortisol
12.1 – 24.2HRV RMSSD
24.8 – 42.3Pre-flight cortisol variability predicted transit-phase immune response magnitude across all four crew members (r = 0.91), suggesting individual stress reactivity as a biomarkerPre-flight
Pre Cortisol CV ↔ Transit IL6 Peak r = 0.91
Pre Cortisol CV
0.2 – 0.2Transit IL6 Peak
4.8 – 5.9Standard Measures3
Astronaut 3 showed elevated resting heart rate throughout transit with no post-flight return to baseline, suggesting sustained cardiovascular deconditioningTransit
Change-point: day 4 · conf 78% · resting_HR
Resting HR
62.0 – 74.0Astronaut 1 showed blood pressure elevation during transit with systolic increase of 12 mmHg, consistent with cardiovascular stress response observed in bed-rest analogsTransit
Change-point: day 3 · conf 74% · systolic_BP
Systolic BP
118.0 – 132.0Diastolic BP
76.0 – 84.0Astronaut 1 showed body mass decline of 2.1 kg during transit, primarily attributable to reduced caloric intake rather than fluid shifts based on albumin stabilityTransit
Body Mass
76.3 – 78.4Albumin
4.0 – 4.2ARCHeR (Behavioral)4
All four crew members showed circadian phase delay during transit, with magnitude correlating inversely with pre-flight circadian robustnessTransit
Change-point: day 2 · conf 82% · circadian_phase_delay
Circadian Phase Delay
0.0 – 2.1Sleep Onset Variability
15.0 – 55.0Astronaut 2 showed the most severe sleep fragmentation during transit, with wake-after-sleep-onset exceeding pre-flight baseline by 340%Transit
Change-point: day 3 · conf 91% · WASO
WASO
12.0 – 62.0Sleep Efficiency
0.6 – 0.9Astronaut 4 demonstrated the fastest post-flight circadian re-entrainment, returning to baseline phase within 48 hours of landingPost-flight
Change-point: day 8 · conf 85% · circadian_phase_delay
Circadian Phase Delay
0.0 – 1.6Re Entrainment Rate
0.1 – 1.2— no sample days 1, 2, 3, 4, 5, 6 —
Astronaut 4 showed paradoxical improvement in cognitive reaction times during transit, possibly related to maintained sleep quality and absence of inflammatory responseTransit
Reaction Time
258.0 – 285.0Immune Biomarkers4
Astronaut 1 exhibited a transient lymphocyte redistribution during early transit consistent with acute stress response, normalizing by mission day 6Transit
Change-point: day 3 · conf 86% · lymphocyte_pct
Lymphocyte Pct
20.1 – 32.8Neutrophil Pct
57.8 – 71.2Astronaut 2 showed significant IL-10 elevation during transit alongside IL-6, suggesting an active anti-inflammatory compensatory responseTransit
Change-point: day 5 · conf 81% · IL-10
IL-10
2.1 – 5.8IL-6 To IL-10 Ratio
0.6 – 1.3Astronaut 3 exhibited persistent post-flight immune activation with CRP remaining elevated 14 days after return, unlike the rapid normalization seen in other crew membersPost-flight
CRP
0.9 – 3.4WBC
6.2 – 8.4Astronaut 4 maintained immune stability throughout all mission phases — the only crew member without significant inflammatory marker changesTransit
IL-6
1.0 – 1.4CRP
0.7 – 1.0